Dow Flat Again as Trade Buzz Does Nothing for Stocks

A number of drug stocks are outperforming today

Dec 10, 2019 at 12:03 PM
facebook twitter linkedin


It's another day of weak price action for stocks on Wall Street, with traders mostly holding tight ahead of tomorrow's Fed decision. Ahead of the opening bell, it looked as though apparent headway in U.S.-China trade relations could lift stocks, but the risk-off sentiment has remained. The Dow Jones Industrial Average (DJI) and S&P 500 Index (SPX) are essentially flat at the halfway point, while the Nasdaq Composite (IXIC) outperforms slightly thanks to some big moves from drug stocks.

midday market stats dec 10

One name seeing unusual options trading is CVS Health Corp (NYSE:CVS), as the stock slumps 2.8% to $72.93, breaking support at the 20-day moving average. Put volume is running at twice the expected clip, and there are new positions opening at the December 73 put. Those buying the contract are expecting more downside in the coming weeks. CVS shares hit a new 52-week high of $77 just two weeks ago, and their 14-day Relative Strength Index (RSI) has been moving lower out of overbought conditions since that time.

One of the best stocks today is Magenta Therapeutics Inc (NASDAQ:MGTA), thanks to a gene therapy breakthrough. The shares have gained 16.6% to trade at $14.92, putting them on pace for their highest close since June. MGTA is now up 161% on a year-to-date basis.

Another healthcare stock on the rise is bluebird bio Inc (NASDAQ:BLUE), last seen 8% higher at $82.72. This comes after the drugmaker last evening presented data for its CAR-T cell therapy in patients with multiple myeloma, and Jefferies suggested that even higher doses of the treatment could result in better data down the road. BLUE shares are still fairly close to 52-week-low territory, though, and the 50-day moving average remains a level of chart resistance.

blue stock dec 10

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report
 


 


 
Special Offers from Schaeffer's Trading Partners